49 results about "Molecular pathway" patented technology

Marker levels and forms can be modulated in patients having vascular disease when sufficient vascular tissue is removed. The markers can be, e.g., from tissue, blood or lymph. The markers are typically involved in molecular pathways which are in turn modulated. Atherectomy catheters are used for accomplishing sufficient removal of vascular tissue to effect the modulations.

The present invention relates to the discovery of a novel molecular pathway involved in long-term hyperexcitability of sensory neurons, which, in higher animals, is associated with persistent pain. It is based on the discovery that, following injury to an axon of a neuron, an increase in nitric oxide synthase activity results in increased nitric oxide production, which, in turn, activates guanylyl cyclase, thereby increasing levels of cGMP. Increased cGMP results in activation of protein kinase G (“PKG”), which then is retrogradely transported along the axon to the neuron cell body, where it phosphorylates MAPKerk.

The present invention relates to the compositions, methods, and applications of a novel approach to selective inhibition of several cellular or molecular targets with a single small molecule. More specifically, the present invention relates to multi-functional small molecules wherein one functionality is capable of inhibiting histone deacetylases (HDAC) and the other functionality is capable of inhibiting a different cellular or molecular pathway involved in aberrant cell proliferation, differentiation or survival.

The present invention provides methods and systems useful in determining molecular pathways and elements of molecular pathways. In particular, the present invention provides for the discovery of new molecular pathway elements using Bayesian networks and gene expression information.

The invention relates to establishment and application of a model for screening medicines for treating Alzheimer disease, and aims to provide a transgenic Dosophila melanogaster model for studying molecular pathway of pathogenesis progress of Alzheimer disease and drug screening. The invention obtains stable heritable novel Drosophila melanogaster variety by successive crossing of available transgenic Drosophila melanogaster. The novel disease model can simulate the in vivo generation and metabolism processes of major pathogenic genes of Alzheimer disease, and reproduce the pathogenesis process of the disease. The Drosophila melanogaster model provided by the invention is proven by a variety of indicators closely related to the symptoms of disease, including survive curve, mobility and learning and memory indexes and in vivo experiments, to be distinctly different from other Alzheimer disease Dosophila melanogaster models in all respects.

The invention provides a method for ex vivo expansion of human vascular endothelial progenitor cells in a low oxygen condition. The method comprises the following steps: separating EPCs from human bone marrow, culturing the EPCs in an incubator in the low oxygen condition, and ensuring that the low oxygen condition adopts a 1 percent O2 low oxygen condition. Gene expression to the EPCs by the lowoxygen condition comprises various gene differential expression, and at least relates to the following biological processes: reaction of cells to fatty acid, and adjustment of positive regulation of the activity of ubiquitin-protein ligase with transformed caryomitosis cell cycles. Compared with normoxia culture, the culture method has the advantages that low oxygen environment is more similar tobone marrow microenvironment, and is more beneficial to keeping the primary characteristics of the EPCs; the method performs molecular level evaluation on change of gene expression in EPCs caused by different culture methods, gives differential expression genes in which the low oxygen condition or anoxic condition affects cell dryness and molecular pathways of the differential expression genes, and is applied to improvement of the current stem cells.

The invention belongs to the immunity and molecular biological detection technology field, and discloses a systemic lupus erythematosus lesion immune abnormality detection method based on circRNA. Themethod comprises the steps of collecting peripheral blood mononuclear cell PBMCs specimen, and carrying out detection analysis on gene expression through an RNA-seq sequencing technology; picking out20 genes with significant difference; based on circRNA involved transcription post regulation, performing matching analysis on candidate genes, and screening out miRNA with targeted combination; andby performing summarizing on the targeted combined miRNA, screening out miRNA with representative research value from SLE. From cell and molecular levels, the mode of action and molecular mechanism inlymphocyte immune balance abnormal regulation SLE pathogenesis can be further researched deeply, the mediated signal pathway is explicit and the molecular pathway for developing functional effects ofcircRNA is determined.

Mechanisms nourish stem cells for organ regeneration and prevent alcohol related diseases such as Fetal Alcohol Syndrome (FAS) and Liver Sclerosis. These stem cell nutrients have been found to positively affect the skin, liver, brain neurons, pancreas, and the GI tract. Cholesterol supplementation prevents fetal alcohol spectrum defects (FASD) in alcohol-exposed zebra fish embryos. Using the zebra fish model, alcohol was found to interfere with embryonic development by disrupting cholesterol-dependent activation of a critical signaling molecule, sonic hedgehog (Shh). Cholesterol supplementation of the alcohol-exposed embryos restored the functionality of the molecular pathway and prevented development of FASD-like defects. Novel biomarkers were identified for diagnosing alcohol related diseases by lipid chemical analysis and Raman Spectroscope.

We previously reported that NKG2A, a key inhibitory ligand for HLA-E, is expressed on activated TH2, but not TH1, cells. Here we measured cytokine expression in ex vivo TH2 cells and in a mouse model of asthma upon activation with antiCD3/28 and challenge with an NKG2A-specific agonist We show that signaling through NKG2A modulates Th2 cell effector function. This new molecular pathway data provides a novel explanation and treatment for respiratory virus-associated asthma. RSV and hMPV suppress IFN-γ and HLA-E expression and therefore decrease NKG2A signaling in activated TH2 cells. This results in a relatively robust Th2 response and an unfavorable shift in Th1/Th2 balance. The data presented here suggest that increasing signaling via the NKG2A receptor suppresses Th2 effector function and could positively impact Th1/Th2 balance in asthma.

Disclosed is a category of chromatin peptide medicinal molecules capable of blocking human cell anoxybiotic reaction channels, the molecules are DNA compatible structure domain sequences of the related transcription factors or their bionic molecules or derivatives containing 5-100 amino acid residues, they can be specifically bond to HIF-1 alpha self-promotors or transcription factor driven over 40 downstream gene promotors expressed thereby, the molecules can close the molecular channels for cell anoxybiotic reactions including cell sugar glycolysis reaction and/or immunological inflammation reaction and/or vessel generation reaction, thus closing the non-controlled propagation of late stage cancer cells or chronic inflammation cells under anoxybiotic conditions.

The invention discloses biomedical application of ophiobollin to preparation of a Gli gene inhibitor and a liver cancer prevention and treatment drug. The invention discovers that ophiobollin A and Cand 6-epi-ophiobolin N can significantly inhibit the proliferation of liver cancer cells through inhibiting Gli1 and Gli2 gene expression, and the inhibiting effect shows an obvious dosage dependence;the ophiobollin A and C and the 6-epi-ophiobolin N are effective inhibitors for Gli1 and Gli2 genes and can be used for preparing the liver cancer prevention and treatment drug. Technical personnel in the field know that the inhibition of the Gli1 and Gli2 gene expression is a more mature anticancer molecular pathway, and the ophiobollin A and C and the 6-epi-ophiobolin N play an anti-cancer rolethrough the pathway. The prior art does not disclose research results of the invention.

The invention discloses a preparation method of nano-magnets and belongs to the technical field of industrial preparation. Compared with ordinary magnets, the same-volume nano-magnets in a magnetic field generate more molecules with the molecular circulation effect, molecular current density generated is greater, ultrafine magnetic powder is in alignment in crystals of silicon dioxide, and coverage of electronic shield effect generated in an overlapping manner among molecular circulation is weakened. A sweet wormwood extract added is rich in artemisinin which is of an alcohol peroxide compoundand has good antimicrobial resistance, hydrogen bonds exist between the artemisinin and silicon dioxide molecules in the nano-magnets, and contact molecular binding is achieved; in the magnetic field, high-valence metal ions in the ultrafine magnetic powder are easy to attract electrons in alcohol peroxide, the electrons finally return to the alcohol peroxide through hole conduction of the crystals of the silicon dioxide, molecular pathways are formed through circulation, conduction velocity of the electrons is fastened, strength of molecular circulation is increased, and saturation magneticflux density of the nano-magnets is improved.

The invention belongs to the technical field of molecular biology, and particularly relates to application of a WDR1 gene in preparation of a product for treating and detecting the non-small cell lungcancer. The invention firstly discloses that a human WDR1 gene is a valuable biomarker in an occurrence and development process of a tumor, and is expected to be a potential target of a non-small cell lung cancer treatment strategy. The human WDR1 gene has a certain application value in preparation of a non-small cell lung cancer screening and detecting product and a prognostic detection productfor a non-small cell lung cancer treatment effect, provides a certain clue and a new visual angle for early detection, diagnosis and prognosis of the NSCLC (non-small cell lung cancer), is favorable for developing a target drug for NSCLC treatment and improving the treatment status of the NSCLC, and has a potential and good application prospect in the field of tumor detection, diagnosis and treatment. The invention provides a new theoretical basis and direction for describing a potential molecular pathway and mechanism of NSCLC occurrence and development.

The invention provides a method for detecting a human placenta-originated mesenchymal stem cells (MSCs) mechanism with the effects of inhibiting the activity and the proliferation of T cells in vitro. In view of the important role of costimulatory molecules in the activation and the proliferation of the T cells, the invention provides a bold speculation that the human placenta-originated MSCs show a negative regulation effect on the T cells in vitro, which may be related to the high-expression negative costimulatory molecules namely programmed death ligand-1 (PD-L1). The method comprises the steps of: firstly verifying that PMSCS (Placentaderived Mesenchymal Stem Cells) has an obvious inhibiting effect on the T-cell activation through experiments, taking negative costimulatory molecules namely the PD-L1 as an entry point, analyzing the role of the PD-L1 in the PMSCS-mediated effects of inhibiting the activity and the proliferation of the T cells in vitro through experiments such as flow cytometer detection, immunofluorescent staining, 3H-TdR (3H-Thymidine Riboside) mixing method, ELISA (Enzyme Linked Immunosorbent Assay) and the like and accordingly verifying that the PD1-PD-L1 molecular pathway is the main signaling mechanism of the PMCSC for regulating the immune tolerance of the T cells in vitro.

The invention provides application of a gold complex in preparation of a medicine for treating novel coronavirus pneumonia, and belongs to the technical field of biological medicine. The gold complex can effectively inhibit the catalytic activity of the Mpro protein and inhibit the replication of the SARS-CoV-2 live virus in the cells in the living cells. The gold complex can significantly inhibit activation of NFkB inflammatory molecular pathways of macrophages and lung bronchial cells, thereby reducing expression and secretion of inflammatory factors IL-6, IL-1beta and TNF-alpha. The gold complex can inhibit lung tissue virus replication and inhibit inflammatory injury of animal lung tissues on a COVID-19 model animal. The gold complex not only can inhibit the replication of the SARS-CoV-2 in cells and animals, but also can directly inhibit the damage of immune inflammation storm caused by virus infection to living lung tissues.

Aspects of the present invention include compositions and methods for discovering novel compositions and applying said compositions in treating medical conditions including aging, degenerative disease, wound treatment, and cancer through the modulation of molecular pathways regulating regeneration and senolysis by means of altering the embryonic-fetal and prenatal/postnatal transitional states of mammalian cells.

A method of obtaining a non-human mammal susceptible to adenovirus-mediated gene delivery, a method for such delivery, and a transgenic non-human mammal susceptible to adenovirus-mediated gene delivery, and more specifically a trans-genic mouse that expresses a cytoplasmically truncated human Coxsackievirus and Adenovirus Receptor (hCAR) in essentially all tissues thereof. The mammal allows for efficient infections at low multiplicity of infection (MOI) into cells that are normally resistant or not very susceptible to adenovirus-mediated gene delivery, such as spleenocytes and dendritic cells (DC). The hCAR transgenic mammal is highly susceptible to adenovirus-mediated gene transfer and will be a useful tool to probe gene function in development and to elucidate molecular pathways, dynamic properties and differentiation mechanisms in non-transformed cells.